MLYS
Mineralys Therapeutics, Inc.
$23.69
-5.43%
$2.0B
No data for this timeframe.
Vol
Market Cap$2.0B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders8 funds
Inst. Value$416.9M
Inst. Activity5 buys / 1 sells
Insider Activity2B / 15S
Insider Net $$6.0M
SEC Reports8
Press Releases5
Recent Activity
Dec 22, 2026
fda_pdufa
PDUFA: MLYS — lorundrostat in hypertension — 2026-12-22
FDA target action date 2026-12-22 for MLYS (Mineralys Therapeutics, Inc.). Drug: lorundrostat. Indic
Jun 3, 2026
SEC
Mineralys Therapeutics entered into a $200M one-time cash payment to Tanabe Pharma to buy out all future royalty obligat
8-K — Impact 7/10
Jun 3, 2026
Press
Mineralys Therapeutics repurchased its royalty obligation to Tanabe for $200M upfront (up to $100M in milestones), secur
Impact 7/10
May 30, 2026
Press
Mineralys Therapeutics presented positive post-hoc data from the Phase 3 Launch-HTN trial at ESH 2026, showing lorundros
Impact 7/10
May 18, 2026
Insider
Rodman David Malcom sold 417 shares
Chief Medical Officer @ $15.44 ($6.4K)
May 18, 2026
Insider
Rodman David Malcom sold 417 shares
Chief Medical Officer @ $27.55 ($11.5K)
May 18, 2026
Insider
Rodman David Malcom sold 417 shares
Chief Medical Officer @ $0.00 ($0.00)
May 12, 2026
SEC
Officer David Malcom Rodman filed a Form 144 to sell 6,348 shares of Mineralys Therapeutics (MLYS) valued at approximate
144 — Impact 2/10
Price Targets
$49.00
+106.8% upside
Strong Buy
Current $23.69
Low $30.00
Median $52.00
High $56.00
8 analysts
$30.00
$56.00
Analyst Ratings
5Strong Buy
9Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 27, 2026 | TD Cowen | INITIATE | Buy |
| Mar 13, 2026 | B of A Securities | MAINTAIN | Buy → Buy |
| Dec 19, 2025 | Stifel | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.54 ▼ -15.1% | $-0.61 — $-0.44 | 19% YoY | 8 |
| Next Q | $-0.56 ▼ -11.6% | $-0.63 — $-0.41 | -8% YoY | 8 |
| Current FY | $-2.24 ▼ -7.1% | $-2.53 — $-1.74 | 2% YoY | 8 |
| Next FY | $-2.10 ▼ -16.0% | $-3.28 — $1.01 | 6% YoY | 8 |
Latest Reports
MIXED
8-K
7/10
Mineralys Therapeutics entered into a $200M one-time cash payment to Tanabe Pharma to buy out all future royalty obligat
Jun 3, 2026
BULLISH
Press
7/10
Mineralys Therapeutics repurchased its royalty obligation to Tanabe for $200M upfront (up to $100M in milestones), secur
Jun 3, 2026
NEUTRAL
144
2/10
Officer David Malcom Rodman filed a Form 144 to sell 6,348 shares of Mineralys Therapeutics (MLYS) valued at approximate
May 12, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $183.5M | DOUBLED |
| VANGUARD GROUP INC | $121.7M | ADD |
| BANK OF AMERICA CORP | $35.8M | ADD |
| MORGAN STANLEY | $23.2M | TRIM |
| TWO SIGMA INVESTMENTS, LP | $22.2M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 18, 2026 | Rodman David | M | $6.4K |
| May 18, 2026 | Rodman David | SELL | $11.5K |
| May 18, 2026 | Rodman David | M | $0.00 |
| May 13, 2026 | Rodman David | SELL | $401.8K |
| May 13, 2026 | Rodman David | M | $0.00 |
8 institutional holders with $416.9M total value (11,487,735 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, BANK. Net buying activity: 5 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 5,057,509 | $183.5M | 44.0% | DOUBLED +144.2% |
| 2 | VANGUARD GROUP INC | 3,352,880 | $121.7M | 29.2% | ADD +29.8% |
| 3 | BANK OF AMERICA CORP /DE/ | 987,280 | $35.8M | 8.6% | ADD +28.5% |
| 4 | MORGAN STANLEY | 639,507 | $23.2M | 5.6% | TRIM -53.6% |
| 5 | TWO SIGMA INVESTMENTS, LP | 610,403 | $22.2M | 5.3% | NEW |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 461,300 | $16.7M | 4.0% | ADD +26.2% |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 322,100 | $11.7M | 2.8% | DOUBLED +579.5% |
| 8 | WELLS FARGO & COMPANY/MN | 56,756 | $2.1M | 0.5% | ADD +88.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | DOUBLED | 2,071,255 | 5,057,509 | +144.2% | $183.5M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 768,265 | 987,280 | +28.5% | $35.8M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 1,376,998 | 639,507 | -53.6% | $23.2M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 610,403 | — | $22.2M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 47,400 | 322,100 | +579.5% | $11.7M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 30,054 | 56,756 | +88.8% | $2.1M | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 2,326,449 | 3,018,999 | +29.8% | $114.5M | 2025-Q3 |
| FMR LLC | DOUBLED | 304,886 | 2,071,255 | +579.4% | $78.5M | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 587,830 | 1,376,998 | +134.3% | $52.2M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 263,356 | 768,265 | +191.7% | $29.1M | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 324,205 | 409,187 | +26.2% | $15.5M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 176,926 | 47,400 | -73.2% | $1.8M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 147,222 | 263,356 | +78.9% | $3.6M | 2025-Q2 |
| UBS Group AG | DOUBLED | 37,161 | 115,139 | +209.8% | $1.6M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 48,532 | 0 | -100.0% | $0.00 | 2025-Q2 |
| VANGUARD GROUP INC | ADD | 1,432,042 | 2,035,506 | +42.1% | $32.3M | 2025-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 214,906 | 270,175 | +25.7% | $4.3M | 2025-Q1 |
| CITADEL ADVISORS LLC | NEW | — | 205,662 | — | $3.3M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 119,500 | 177,300 | +48.4% | $2.8M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 48,532 | — | $770.7K | 2025-Q1 |
| UBS Group AG | DOUBLED | 16,100 | 48,885 | +203.6% | $601.8K | 2024-Q4 |
| CITADEL ADVISORS LLC | EXIT | 16,236 | 0 | -100.0% | $0.00 | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 213,599 | — | $2.6M | 2024-Q3 |
6 unique insiders with 17 transactions. Net insider value: $6.0M ($8.8M bought, $2.8M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 18, 2026 | Rodman David Malcom | Chief Medical Officer | M | 417 | $15.44 | $6.4K |
| May 18, 2026 | Rodman David Malcom | Chief Medical Officer | SELL | 417 | $27.55 | $11.5K |
| May 18, 2026 | Rodman David Malcom | Chief Medical Officer | M | 417 | $0.00 | $0.00 |
| May 13, 2026 | Rodman David Malcom | Chief Medical Officer | SELL | 14,056 | $28.58 | $401.8K |
| May 13, 2026 | Rodman David Malcom | Chief Medical Officer | M | 3,541 | $0.00 | $0.00 |
| May 13, 2026 | Rodman David Malcom | Chief Medical Officer | M | 3,541 | $10.20 | $36.1K |
| May 12, 2026 | Rodman David Malcom | Chief Medical Officer | M | 6,348 | $1.08 | $6.9K |
| May 12, 2026 | Rodman David Malcom | Chief Medical Officer | SELL | 6,348 | $29.36 | $186.3K |
| May 12, 2026 | Rodman David Malcom | Chief Medical Officer | M | 6,348 | $0.00 | $0.00 |
| May 11, 2026 | Rodman David Malcom | Chief Medical Officer | M | 2,171 | $16.00 | $34.7K |
| May 11, 2026 | Rodman David Malcom | Chief Medical Officer | SELL | 2,171 | $29.71 | $64.5K |
| May 11, 2026 | Rodman David Malcom | Chief Medical Officer | M | 2,171 | $0.00 | $0.00 |
| Apr 17, 2026 | Rodman David Malcom | Chief Medical Officer | M | 416 | $15.44 | $6.4K |
| Apr 17, 2026 | Rodman David Malcom | Chief Medical Officer | SELL | 416 | $31.33 | $13.0K |
| Apr 17, 2026 | Rodman David Malcom | Chief Medical Officer | M | 416 | $0.00 | $0.00 |
| Apr 15, 2026 | Rodman David Malcom | Chief Medical Officer | SELL | 6,348 | $27.66 | $175.6K |
| Apr 13, 2026 | Congleton Jon | Chief Executive Officer | SELL | 15,730 | $26.83 | $422.0K |
| Apr 13, 2026 | Rodman David Malcom | Chief Medical Officer | M | 6,349 | $1.08 | $6.9K |
| Apr 13, 2026 | Rodman David Malcom | Chief Medical Officer | M | 6,349 | $0.00 | $0.00 |
| Apr 13, 2026 | Rodman David Malcom | Chief Medical Officer | SELL | 14,058 | $26.54 | $373.1K |
| Apr 9, 2026 | Rodman David Malcom | Chief Medical Officer | M | 2,170 | $16.00 | $34.7K |
| Apr 9, 2026 | Rodman David Malcom | Chief Medical Officer | SELL | 2,170 | $27.38 | $59.4K |
| Apr 9, 2026 | Rodman David Malcom | Chief Medical Officer | M | 2,170 | $0.00 | $0.00 |
| Mar 31, 2026 | Karydas Daphne | Director | M | 3,000 | $12.02 | $36.1K |
| Mar 31, 2026 | Karydas Daphne | Director | SELL | 3,000 | $25.00 | $75.0K |
| Mar 31, 2026 | Karydas Daphne | Director | M | 3,000 | $0.00 | $0.00 |
| Mar 31, 2026 | Congleton Jon | Chief Executive Officer | SELL | 19,364 | $25.50 | $493.8K |
| Mar 30, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | BUY | 58,300 | $24.16 | $1.4M |
| Mar 27, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | BUY | 310,700 | $23.67 | $7.4M |
| Mar 17, 2026 | Rodman David Malcom | Chief Medical Officer | SELL | 417 | $25.65 | $10.7K |
| Mar 17, 2026 | Rodman David Malcom | Chief Medical Officer | M | 417 | $15.44 | $6.4K |
| Mar 17, 2026 | Rodman David Malcom | Chief Medical Officer | M | 417 | $0.00 | $0.00 |
| Mar 13, 2026 | Rodman David Malcom | Chief Medical Officer | SELL | 10,726 | $25.91 | $277.9K |
| Mar 13, 2026 | Rodman David Malcom | Chief Medical Officer | M | 3,542 | $10.20 | $36.1K |
| Mar 13, 2026 | Rodman David Malcom | Chief Medical Officer | M | 3,542 | $0.00 | $0.00 |
| Mar 12, 2026 | Rodman David Malcom | Chief Medical Officer | SELL | 6,348 | $27.37 | $173.7K |
| Mar 12, 2026 | Rodman David Malcom | Chief Medical Officer | M | 6,348 | $0.00 | $0.00 |
| Mar 12, 2026 | Rodman David Malcom | Chief Medical Officer | M | 6,348 | $1.08 | $6.9K |
| Mar 9, 2026 | Rodman David Malcom | Chief Medical Officer | M | 2,171 | $0.00 | $0.00 |
| Mar 9, 2026 | Rodman David Malcom | Chief Medical Officer | SELL | 2,171 | $26.84 | $58.3K |
| Mar 9, 2026 | Rodman David Malcom | Chief Medical Officer | M | 2,171 | $16.00 | $34.7K |
| Feb 19, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | A | 6,200 | $0.00 | $0.00 |
| Feb 19, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | A | 8,300 | $0.00 | $0.00 |
| Feb 19, 2026 | Congleton Jon | Chief Executive Officer | A | 140,900 | $0.00 | $0.00 |
| Feb 19, 2026 | Congleton Jon | Chief Executive Officer | A | 187,900 | $0.00 | $0.00 |
| Feb 19, 2026 | SBLENDORIO GLENN | Director | A | 6,200 | $0.00 | $0.00 |
| Feb 19, 2026 | SBLENDORIO GLENN | Director | A | 8,300 | $0.00 | $0.00 |
| Feb 19, 2026 | Gold Alexander M | Director | A | 6,200 | $0.00 | $0.00 |
| Feb 19, 2026 | Gold Alexander M | Director | A | 8,300 | $0.00 | $0.00 |
| Feb 19, 2026 | Karydas Daphne | Director | A | 6,200 | $0.00 | $0.00 |
8 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 1 mixed, 6 neutral. Avg impact: 3.6/10.
MIXED
8-K
7/10
Mineralys Therapeutics entered into a $200M one-time cash payment to Tanabe Pharma to buy out all fu
Jun 3, 2026
NEUTRAL
144
2/10
Officer David Malcom Rodman filed a Form 144 to sell 6,348 shares of Mineralys Therapeutics (MLYS) v
May 12, 2026
NEUTRAL
144
2/10
Officer David Rodman filed a Form 144 notice of intent to sell 2,171 shares of Mineralys Therapeutic
May 11, 2026
NEUTRAL
144
2/10
David Rodman, an officer of Mineralys Therapeutics, filed a Form 144 notifying intent to sell 416 sh
Apr 17, 2026
BEARISH
CLUSTER
7/10
Two top executives at Mineralys Therapeutics — the CEO and Chief Medical Officer — sold shares in a
Apr 16, 2026
NEUTRAL
144
3/10
Jon Congleton, an officer of Mineralys Therapeutics, filed a Form 144 to notify intent to sell 15,73
Apr 13, 2026
NEUTRAL
144
3/10
David Rodman, an officer of Mineralys Therapeutics, filed a Form 144 to notify intent to sell up to
Apr 13, 2026
NEUTRAL
DEFA14A
3/10
Analysis based on filing metadata only — document content was unavailable
Apr 8, 2026
BULLISH
7/10
Mineralys Therapeutics repurchased its royalty obligation to Tanabe for $200M upfront (up to $100M i
Jun 3, 2026
BULLISH
7/10
Mineralys Therapeutics presented positive post-hoc data from the Phase 3 Launch-HTN trial at ESH 202
May 30, 2026
NEUTRAL
4/10
Mineralys Therapeutics announced that new data from its Phase 3 LAUNCH-HTN trial of lorundrostat in
May 18, 2026
BULLISH
8/10
Mineralys Therapeutics reported its fourth quarter and full-year 2025 financial results, highlighted
Mar 12, 2026
BULLISH
8/10
The FDA has accepted Mineralys Therapeutics' New Drug Application (NDA) for lorundrostat, a treatmen
Mar 9, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 16 analysts: 5 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$49.00 mean target
+106.8% upside
Strong Buy (1.20)
$30.00 Low
$56.00 High
| Metric | Value |
|---|---|
| Current Price | $23.69 |
| Target Low | $30.00 |
| Target Mean | $49.00 |
| Target Median | $52.00 |
| Target High | $56.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.20) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.54 | $-0.61 | $-0.44 | 18.9% | -15.1% | 0↑ 1↓ | $0.0B | 0.0% | 8 |
| Next Q 2026-09-30 |
$-0.56 | $-0.63 | $-0.41 | -8.4% | -11.6% | 0↑ 1↓ | $0.0B | 0.0% | 8 |
| Current FY 2026-12-31 |
$-2.24 | $-2.53 | $-1.74 | 2.2% | -7.1% | 0↑ 1↓ | $0.0B | 0.0% | 8 |
| Next FY 2027-12-31 |
$-2.10 | $-3.28 | $1.01 | 6.4% | -16.0% | 1↑ 0↓ | $0.1B | 0.0% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.535 | |
| 7d ago | $-0.536 | +0.001 |
| 30d ago | $-0.465 | -0.070 |
| 60d ago | $-0.468 | -0.067 |
| 90d ago | $-0.535 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 27, 2026 | TD Cowen | INITIATE | — | Buy |
| Mar 13, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Dec 19, 2025 | Stifel | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 9 | 2 | 0 | 0 | 88% | |
| May 1, 2026 | 5 | 9 | 2 | 0 | 0 | 88% | |
| Apr 1, 2026 | 5 | 8 | 2 | 0 | 0 | 87% | |
| Mar 1, 2026 | 5 | 8 | 2 | 0 | 0 | 87% | |
| Feb 1, 2026 | 5 | 8 | 2 | 0 | 0 | 87% | |
| Jan 1, 2026 | 5 | 8 | 2 | 0 | 0 | 87% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Dec 22, 2026
fda_pdufa
PDUFA: MLYS — lorundrostat in hypertension — 2026-12-22
FDA target action date 2026-12-22 for MLYS (Mineralys Therapeutics, Inc.). Drug: lorundrostat. Indication: hypertension. FDA assigned PDUFA target act
Jun 3, 2026
Clinical Trial
Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
Phase Phase 2 — COMPLETED
Jun 3, 2026
other
Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
<p>RADNOR, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing med
Jun 3, 2026
contract
Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing
<p align="center"><em>– </em>Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million
Jun 1, 2026
short_volume
Short Volume: MLYS — 55.1% short (0.3M / 0.6M)
Short: 326,118 | Exempt: 0 | TRF Vol: 591,824 | Short Ratio: 55.1% | Off-exchange volume (dark pool + OTC)
May 30, 2026
fda
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
<p align="center"><em>– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood
May 28, 2026
short_volume
Short Volume: MLYS — 56.7% short (0.4M / 0.7M)
Short: 395,830 | Exempt: 0 | TRF Vol: 698,089 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)
May 18, 2026
fda
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
<p align="center"><em>– Oral presentation highlights efficacy and safety profile of lorundrostat in patients with uncontrolled hypertension and chroni
May 6, 2026
earnings
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="center"><em>– NDA for lorundrostat in adults with hypertension accepted by FDA; assigned PDUFA target date of December 22, 2026 –</em></p>
May 6, 2026
earnings_calendar
MLYS Q1 2026 Earnings Scheduled — 2026-05-06
May 5, 2026
other
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
<p>RADNOR, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medi
May 2, 2026
Clinical Trial
Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
Phase Phase 3 — COMPLETED
May 1, 2026
short_volume
Short Volume: MLYS — 55.2% short (0.5M / 0.9M)
Short: 516,103 | Exempt: 0 | TRF Vol: 934,361 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
Apr 16, 2026
short_volume
Short Volume: MLYS — 75.3% short (0.5M / 0.6M)
Short: 469,712 | Exempt: 0 | TRF Vol: 624,060 | Short Ratio: 75.3% | Off-exchange volume (dark pool + OTC)
Apr 15, 2026
short_volume
Short Volume: MLYS — 62.8% short (0.9M / 1.5M)
Short: 915,880 | Exempt: 600 | TRF Vol: 1,457,894 | Short Ratio: 62.8% | Off-exchange volume (dark pool + OTC)
Apr 7, 2026
short_volume
Short Volume: MLYS — 72.3% short (0.5M / 0.7M)
Short: 470,530 | Exempt: 0 | TRF Vol: 650,820 | Short Ratio: 72.3% | Off-exchange volume (dark pool + OTC)
Apr 6, 2026
short_volume
Short Volume: MLYS — 66.0% short (0.4M / 0.6M)
Short: 417,856 | Exempt: 0 | TRF Vol: 633,090 | Short Ratio: 66.0% | Off-exchange volume (dark pool + OTC)